Atossa Therapeutics Inc
ATOS
Company Profile
Business description
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Contact
1448 NW Market Street
Suite 500
SeattleWA98107
USAT: +1 206 588-0256
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
14
Stocks News & Analysis
stocks
Tesla: valuation is key consideration in merger talks with SpaceX
We see regulatory risk from both the US and Chinese governments.
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,921.00 | 15.20 | 0.17% |
| CAC 40 | 7,782.82 | 28.44 | -0.36% |
| DAX 40 | 25,181.65 | 190.10 | -0.75% |
| Dow JONES (US) | 52,215.16 | 652.82 | -1.23% |
| FTSE 100 | 10,690.36 | 34.67 | -0.32% |
| HKSE | 23,193.94 | 100.57 | 0.44% |
| NASDAQ | 25,955.34 | 53.52 | -0.21% |
| Nikkei 225 | 62,503.82 | 189.34 | -0.30% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,623.68 | 39.75 | -0.52% |
| S&P/ASX 200 | 8,805.60 | 10.40 | 0.12% |
| SSE Composite Index | 3,683.92 | 6.56 | -0.18% |